What Does Emcitate Do for MCT8 Deficiency?
Emcitate (tiratricol) is now the first FDA-approved drug for MCT8 deficiency. It's a daily oral tablet that lowers the toxic T3 flooding the heart, muscles, and liver of a boy born with this X-linked disease, and in trials it slowed the wasting and tachycardia that have driven early death. It doesn't cure the severe brain and motor disability that defines the syndrome, but it changes what families can do about the body-wide part of the disease. The earlier a family reaches diagnosis and starts dosing, the more of that benefit stays with the child.
On September 28, 2026, the FDA approved Emcitate (tiratricol) for peripheral thyrotoxicosis in adults and children with MCT8 deficiency, also called Allan-Herndon-Dudley syndrome. It is the first drug approved for the disease in the United States. The label is careful about what it doesn't claim. Emcitate isn't indicated for the severe intellectual and motor disability that defines the syndrome.
How MCT8 deficiency splits into two problems
MCT8 deficiency is an X-linked disease affecting roughly 1 in 70,000 boys, caused by loss-of-function variants in the SLC16A2 gene. The transporter it encodes moves thyroid hormone into cells, and it's the only route into the developing brain. Without it, the brain starves for thyroid hormone during the critical months of neurogenesis and myelination, while the rest of the body sees T3 pile up in the bloodstream. Boys develop severe intellectual disability, hypotonia that evolves into spasticity and dystonia, and, on top of that, a chronic peripheral thyrotoxicosis with tachycardia, hypertension, and progressive underweight. In an international cohort of 151 patients, median survival was about 35 years, with pulmonary infection and sudden unexplained death each accounting for roughly a fifth of deaths. Being underweight between ages 1 and 3 was linked to a much higher risk of dying young.
What the drug proved
Tiratricol is a thyroid hormone analog with an acetic-acid side chain in place of the usual amino-acid side chain. That small change lets it slip into cells without MCT8 and bind thyroid hormone receptors directly. A real-world cohort of 67 patients followed for up to about six years found no new safety signals, and weight-for-age moved out ahead of untreated natural-history controls.
What it hasn't proved, and why age at diagnosis matters
On the brain, the human evidence is preliminary. In mouse models, tiratricol restores myelination when it's started before the equivalent of the third postnatal week. In children, no published cohort has shown reversal of established motor or cognitive deficits: severe hypotonia, absent independent walking, and profound intellectual delay persist on therapy, even when treatment starts as early as a few months of age. Diagnostic delays average roughly 18 months, well past the presumed developmental window, and closing that gap is the single biggest lever families and clinicians have on the neurological side of the disease. If you suspect MCT8 deficiency in an infant boy with developmental delay and unusual thyroid labs, the biochemistry is distinctive: an elevated free T3, a low or normal free T4, and a free T3 to free T4 ratio above 0.75. Genetic confirmation runs on SLC16A2 sequencing.
What Emcitate changes, and what it doesn't
| Domain | What Emcitate does | Strength of evidence |
|---|---|---|
| Heart rate and arrhythmia | Cuts resting tachycardia substantially; premature atrial beats become less frequent | Strong |
| Body weight and growth | Halts wasting; weight-for-age exceeds untreated natural-history controls | Strong |
| Neurodevelopment and motor function | No proven reversal of established deficits in humans; mouse models suggest benefit if started in the first weeks of life | Preliminary in humans |
Getting the drug, using it safely
Egetis Therapeutics expects Emcitate in U.S. pharmacies within 8 to 10 weeks of approval, distributed exclusively through PANTHERx Rare with support through the Egetis RareLink program at 1-844-4EGETIS. It comes as a 350 mcg tablet that's dispersed in water and given once daily, and the dose is adjusted every couple of weeks toward a total T3 below the age-specific midpoint of the normal range. Starting dose is 175 mcg per day for patients weighing 10 kg or less and 350 mcg per day above that. Monitoring has to use liquid chromatography-tandem mass spectrometry T3 assays; tiratricol cross-reacts with standard T3 immunoassays and makes the number look falsely high. The most common adverse effects are diarrhea, vomiting, rash, and increased sweating, and a small share develop transient thyrotoxic symptoms during dose adjustment. The label carries a boxed warning that Emcitate is not for obesity or weight loss.
Where this leaves families
Emcitate is the first drug that reliably quiets the peripheral thyrotoxicosis that has been shortening these boys' lives, and its effect on the brain in humans is still unproven. A prospective trial starting tiratricol in the newborn period with standardized motor and cognitive endpoints, or newborn-screening data showing pre-symptomatic treatment alters the developmental trajectory in humans as it does in mice, would move the neurological claim from preliminary to established. Until then, the evidence supports getting to the diagnosis as early as possible and starting dosing as soon as possible after that.